Treatment of muscle-related disorders with human anti-cacng1 antibodies.

CL202601278A1Pending Publication Date: 2026-07-24REGENERON PHARMACEUTICALS INC

View PDF 0 Cites 0 Cited by

Patent Information

Application Number: CL202601278
Authority / Receiving Office: CL · CL
Patent Type: Applications
Current Assignee / Owner
Priority Date: 2024-02-12
Filing Date: 2026-04-20
Publication Date: 2026-07-24

Application Information

Patent Timeline

12 Feb 2024

Priority

20 Apr 2026

Application

CL202601278

24 Jul 2026

Publication

CL202601278A1

IPC: C07K14/005; C07K16/28; C12N15/86

CPC: C07K16/28; C12N15/86; C07K2317/622; C07K2317/21; C07K2317/92; C07K2317/77; C12N2750/14143; C12N2750/14145

Inventors: STEC Michael; PEFANIS Evangelos

Get more patent work done with AI

Run novelty searches—or use them for FTO, design risk, drafting and technical problem-solving.

Explore More Agents

Novelty Search
Search existing technologies and assess novelty
↗
FTO
Analyze whether a product may infringe others' patents
↗
Design FTO
Check prior-design risk for exterior design
↗
Drafting
Draft patent application text based on a technical solution
↗
Find Solutions with TRIZ
Generate feasible solution to solve your technical challenge
↗
IP MCP Servers
Connect trusted patent search and cited evidence to Claude, Cursor or your own AI workflow
↗

Patent Text Reader

Abstract

Adeno-associated virus (AAV) particles redirected with antibodies to CACNG1 and carrying a therapeutic nucleotide of interest are provided. Methods for manufacturing and using the AAV particles are also provided, for example, to treat a patient in need or to manufacture a drug for that patient.

Need to check novelty before this filing date? Find Prior Art